Acurx Pharmaceuticals Inc. Common Stock (ACXP)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses with honest economics and a margin of safety. Acurx is a clinical-stage antibiotic developer with four employees and no reported revenue in any filed period. Its lead candidate, ibezapolstat, is in Phase 2b for C. difficile infections. In fiscal 2025, ended 2025-12-31, net loss was $8.0M and diluted EPS was -$5.32. In fiscal 2024, ended 2024-12-31, net loss was $14.1M and diluted EPS was -$17.45. In fiscal 2023, ended 2023-12-31, net loss was $14.6M and diluted EPS was -$1.15. More recently, fiscal Q2 2026, the quarter ended 2026-06-30, showed a net loss of $2.3M and diluted EPS of -$0.53. There is no revenue to value. At the 2026-10-13 close, FairStock calculated a market cap of $6.3M, P/B of 0.69, P/E of -0.45, ROE of -128.11%, TTM free cash flow of -$6.2M, FCF yield of -97.8%, Piotroski F-Score of 1/9, and Altman Z-Score of -7.87. Those figures describe a company burning cash and showing financial distress. A P/B below one might suggest asset value, but the assets are likely cash being spent, not productive earning power. There is no competitive moat yet; the only potential edge is a successful drug or patent protection, neither proven. Graham wanted earnings stability, and Buffett wanted durable economics. Acurx has neither. It is a venture-style bet on clinical data, and the risk of dilution or failure is high. Only compelling Phase 2b results plus secured financing would change the investment case.

In plain English: Acurx Pharmaceuticals is a very small clinical-stage company trying to develop antibiotics for serious bacterial infections. It has no product sales yet and has lost money in each recent year, with continued losses in the latest reported quarters. At $1.20 a share, the stock is at its 52-week low; it may look inexpensive compared with its accounting value, but the company is spending cash and its future depends almost entirely on whether its main drug trial succeeds.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer